IPO News Archive
Biotech company BioHeart announces terms

9/6/07


BioHeart, which focuses on using cells derived from a patient's body for treatment of heart damage, filed terms Thursday with the SEC for its upcoming iPO. The company plans to offer 3.6 million shares at a price range of $14 to $16 per share. BMO Capital Markets is the lead manager on the deal.

View IPO Profile: BHRT         
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest